Predictive factors for long-term prognosis in adults with cyanotic congenital heart disease — Japanese multi-center study

2007 ◽  
Vol 120 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Hisanori Sakazaki ◽  
Koichiro Niwa ◽  
Shigeyuki Echigo ◽  
Teiji Akagi ◽  
Makoto Nakazawa
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Predictive Factors ◽  
Congenital Heart ◽  
Cyanotic Congenital Heart Disease ◽  
Long Term Prognosis ◽  
Multi Center Study ◽  
Center Study

Outcome of Adults with Congenital Heart Disease Evaluated for Heart Transplant: A Multi-Center Study

2013 ◽  
Vol 32 (4) ◽  
pp. S165-S166
Author(s):  
D. Boucek ◽  
A.T. Yetman ◽  
E. Yeung ◽  
S. Miyamoto ◽  
A.G. Kfoury ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Heart Transplant ◽  
Congenital Heart ◽  
Multi Center Study ◽  
Center Study

scholarly journals Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children

2016 ◽  
Vol 43 (6) ◽  
pp. 509-513 ◽  
Author(s):  
Glen J. Iannucci ◽  
Olufolake A. Adisa ◽  
Matthew E. Oster ◽  
Michael McConnell ◽  
William T. Mahle
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Congenital Heart ◽  
Cyanotic Congenital Heart Disease ◽  
Cell Disease ◽  
Long Term Outcome ◽  
Cerebrovascular Accidents

Sickle cell disease is a risk factor for cerebrovascular accidents in the pediatric population. This risk is compounded by hypoxemia. Cyanotic congenital heart disease can expose patients to prolonged hypoxemia. To our knowledge, the long-term outcome of patients who have combined sickle cell and cyanotic congenital heart disease has not been reported. We retrospectively reviewed patient records at our institution and identified 5 patients (3 girls and 2 boys) who had both conditions. Their outcomes were uniformly poor: 4 died (age range, 12 mo–17 yr); 3 had documented cerebrovascular accidents; and 3 developed ventricular dysfunction. The surviving patient had developmental delays. On the basis of this series, we suggest mitigating hypoxemia, and thus the risk of stroke, in patients who have sickle cell disease and cyanotic congenital heart disease. Potential therapies include chronic blood transfusions, hydroxyurea, earlier surgical correction to reduce the duration of hypoxemia, and heart or bone marrow transplantation.

Sign in / Sign up

Export Citation Format

Share Document